Jin Honglin, Lovell Jonathan F, Chen Juan, Ng Kenneth, Cao Weiguo, Ding Lili, Zhang Zhihong, Zheng Gang
Ontario Cancer Institute and Campbell Family Cancer Research Institute, University of Toronto, Toronto, Canada ; Department of Medical Biophysics, University of Toronto, Toronto, Canada ; Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, China.
Ontario Cancer Institute and Campbell Family Cancer Research Institute, University of Toronto, Toronto, Canada ; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada.
Cancer Nanotechnol. 2010;1(1-6):71-78. doi: 10.1007/s12645-010-0009-x. Epub 2010 Nov 11.
Targeted nanoparticles have the potential to deliver a large drug payload specifically to cancer cells. Targeting requires that a ligand on the nanoparticle surface interact with a specific membrane receptor on target cells. However, the contribution of the targeting ligand to nanoparticle delivery is often influenced by non-specific nanoparticle uptake or secondary targeting mechanisms. In this study, we investigate the epidermal growth factor (EGF) receptor-targeting specificity of a nanoparticle by dual-color fluorescent labeling. The targeted nanoparticle was a fluorescently labeled, EGF-conjugated HDL-like peptide-phospholipid scaffold (HPPS) and the cell lines expressed EGF receptor linked with green fluorescent protein (EGFR-GFP). Using LDLA7 cells partially expressing EGFR-GFP, fluorescence imaging demonstrated the co-internalization of EGFR-GFP and EGF-HPPS, thus validating its targeting specificity. Furthermore, specific EGFR-mediated uptake of the EGF-HPPS nanoparticle was confirmed using human non-small cell lung cancer A549 cells. Subsequent confocal microscopy and flow cytometry studies delineated how secondary targeting mechanisms affected the EGFR targeting. Together, this study confirms the EGFR targeting of EGF-HPPS in lung cancer cells and provides insight on the potential influence of unintended targets on the desired ligand-receptor interaction.
靶向纳米颗粒有潜力将大量药物有效载荷特异性地递送至癌细胞。靶向作用要求纳米颗粒表面的配体与靶细胞上的特定膜受体相互作用。然而,靶向配体对纳米颗粒递送的贡献常常受到非特异性纳米颗粒摄取或二次靶向机制的影响。在本研究中,我们通过双色荧光标记研究了一种纳米颗粒对表皮生长因子(EGF)受体的靶向特异性。靶向纳米颗粒是一种荧光标记的、与EGF偶联的类高密度脂蛋白肽-磷脂支架(HPPS),细胞系表达与绿色荧光蛋白相连的EGF受体(EGFR-GFP)。使用部分表达EGFR-GFP的LDLA7细胞,荧光成像显示了EGFR-GFP与EGF-HPPS的共内化,从而验证了其靶向特异性。此外,使用人非小细胞肺癌A549细胞证实了EGF-HPPS纳米颗粒通过EGFR介导的特异性摄取。随后的共聚焦显微镜和流式细胞术研究描绘了二次靶向机制如何影响EGFR靶向作用。总之,本研究证实了EGF-HPPS在肺癌细胞中的EGFR靶向作用,并提供了关于非预期靶点对所需配体-受体相互作用潜在影响的见解。